4-Methyl-N-(2-morpholinoethyl)-6-phenylpyridazin-3-amine dihydrochloride

Catalog No. :
ACAFSP971
CAS No. :
25953-17-7
Molecular Formula :
C17H24Cl2N4O
Molecular Weight :
371.31

IUPAC Name:4-methyl-N-(2-morpholinoethyl)-6-phenylpyridazin-3-amine dihydrochloride

4-Methyl-N-(2-morpholinoethyl)-6-phenylpyridazin-3-amine dihydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-Methyl-N-(2-morpholinoethyl)-6-phenylpyridazin-3-amine dihydrochloride
IUPAC Name4-methyl-N-(2-morpholinoethyl)-6-phenylpyridazin-3-amine dihydrochloride
Molecular FormulaC17H24Cl2N4O
Molecular Weight371.31
SMILES[H]Cl.CC1=CC(C2=CC=CC=C2)=NN=C1NCCN3CCOCC3.[H]Cl
InChI KeyGNUCGROXDZMCJI-UHFFFAOYSA-N
SynonymMS-25973 | SPECTRUM1501120 | Prestwick_2 | 4-MORPHOLINEETHANAMINE, N-(4-METHYL-6-PHENYL-3-PYRIDAZINYL)-, DIHYDROCHLORIDE (2) 4-(2-((4-METHYL-6-PHENYL-3-PYRIDAZINYL)AMINO)ETHYL)MORPHOLINE DIHYDROCHLORIDE. | MINAPRINE HYDROCHLORIDE [MART.] | Q27122287 | MIN
CAS No.25953-17-7
PubChem CID33254

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACAFSP971 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACQROT208 route compound structure diagram
    ACQROT20898-80-6 In Stock
  4. Then
  5. ACAFSP971 route product structure diagram
    ACAFSP97125953-17-7
Inquiry

2. ACAFSP971 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACAFSP971 route product structure diagram
    ACAFSP97125953-17-7
Inquiry

Comments (0)